|
TET3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.27510224601224E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.51976217668926E-12 |
| Normal-vs-Stage2 |
9.181100E-03 |
| Normal-vs-Stage3 |
3.22159999999183E-06 |
| Normal-vs-Stage4 |
3.646400E-04 |
| Stage1-vs-Stage2 |
5.782000E-02 |
| Stage1-vs-Stage3 |
1.041190E-01 |
| Stage1-vs-Stage4 |
7.652000E-02 |
| Stage2-vs-Stage3 |
4.919200E-01 |
| Stage2-vs-Stage4 |
7.037200E-01 |
| Stage3-vs-Stage4 |
7.688400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.60735918703404E-12 |
| Normal-vs-AfricanAmerican |
5.624500E-03 |
| Normal-vs-Asian |
2.03210000004894E-06 |
| Caucasian-vs-AfricanAmerican |
9.425400E-01 |
| Caucasian-vs-Asian |
1.297640E-01 |
| AfricanAmerican-vs-Asian |
3.743000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.53020000004389E-08 |
| Normal-vs-Female |
5.22100140898374E-11 |
| Male-vs-Female |
9.127800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.3908874052504E-12 |
| Normal-vs-Age(41-60Yrs) |
1.77029999548495E-08 |
| Normal-vs-Age(61-80Yrs) |
1.059930E-03 |
| Normal-vs-Age(81-100Yrs) |
5.513900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.636100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.387600E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.909620E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.591800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.607760E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.966800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.836700E-03 |
| Classical-VS-Follicular |
3.84692278032617E-13 |
| Classical-VS-Other |
3.109000E-01 |
| Classical-VS-Normal |
4.44089209850063E-16 |
| Tall-VS-Follicular |
3.126300E-02 |
| Tall-VS-Other |
8.260600E-01 |
| Tall-VS-Normal |
2.163600E-03 |
| Follicular-VS-Other |
1.645590E-01 |
| Follicular-VS-Normal |
4.422000E-01 |
| Other-VS-Normal |
1.376450E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.21129999977698E-07 |
| Normal-vs-N1 |
1.92619999994648E-06 |
| N0-vs-N1 |
1.714830E-01 |
|
|
